Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

Kaori Sakurai, Shotaro Chubachi, Hidehiro Irie, Akihiro Tsutsumi, Naofumi Kameyama, Takashi Kamatani, Hidefumi Koh, Takeshi Terashima, Hidetoshi Nakamura, Koichiro Asano, Tomoko Betsuyaku

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammation in chronic obstructive pulmonary disease (COPD) patients. But, a meaningful threshold and the longitudinal changes are unknown. We aimed to investigate the association between NLR and the clinical characteristics of COPD patients and to determine a meaningful threshold and the longitudinal changes for NLR. Methods: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. We performed a blood examination and a pulmonary function test. Blood examination was completed at baseline and annually thereafter, at a time when the disease was stable. Two hundred seventy-four patients who had at least 3 blood examinations over 3 years were included. Results: Baseline NLR was correlated with baseline C-reactive protein (CRP) (r = 0.18, p = 0.003) and SAA (r = 0.34, p < 0.001). We defined an NLR score of 2.7 as the arbitrary cut-off value based on upper quartile points. COPD patients with NLR ≥ 2.7 were older (p = 0.037), had a lower BMI (p = 0.005) and a lower %FEV1 (p = 0.0003) compared to patients with NLR < 2.7. Receiver-operating-characteristic (ROC) curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points. Follow-up analysis over 3 years revealed that the differences in the trends of NLR among the three groups based on the categories of exacerbations (moderate or severe, mild, no exacerbation) were significant (p = 0.006). Conclusions: NLR is associated with COPD severity and exacerbations. For predicting exacerbations, we estimated the threshold of NLR to be 2.7 at baseline.

Original languageEnglish
Article number65
JournalBMC Pulmonary Medicine
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 May 2

Fingerprint

Chronic Obstructive Pulmonary Disease
Neutrophils
Lymphocytes
Respiratory Function Tests
ROC Curve
C-Reactive Protein
Disease Progression
Cohort Studies
Biomarkers
Inflammation

Keywords

  • Acute exacerbation
  • Comorbidity
  • COPD
  • NLR

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sakurai, K., Chubachi, S., Irie, H., Tsutsumi, A., Kameyama, N., Kamatani, T., ... Betsuyaku, T. (2018). Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. BMC Pulmonary Medicine, 18(1), [65]. https://doi.org/10.1186/s12890-018-0639-z

Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. / Sakurai, Kaori; Chubachi, Shotaro; Irie, Hidehiro; Tsutsumi, Akihiro; Kameyama, Naofumi; Kamatani, Takashi; Koh, Hidefumi; Terashima, Takeshi; Nakamura, Hidetoshi; Asano, Koichiro; Betsuyaku, Tomoko.

In: BMC Pulmonary Medicine, Vol. 18, No. 1, 65, 02.05.2018.

Research output: Contribution to journalArticle

Sakurai, K, Chubachi, S, Irie, H, Tsutsumi, A, Kameyama, N, Kamatani, T, Koh, H, Terashima, T, Nakamura, H, Asano, K & Betsuyaku, T 2018, 'Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients', BMC Pulmonary Medicine, vol. 18, no. 1, 65. https://doi.org/10.1186/s12890-018-0639-z
Sakurai, Kaori ; Chubachi, Shotaro ; Irie, Hidehiro ; Tsutsumi, Akihiro ; Kameyama, Naofumi ; Kamatani, Takashi ; Koh, Hidefumi ; Terashima, Takeshi ; Nakamura, Hidetoshi ; Asano, Koichiro ; Betsuyaku, Tomoko. / Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. In: BMC Pulmonary Medicine. 2018 ; Vol. 18, No. 1.
@article{9e25cb7b94d64c50909ce69a193f737d,
title = "Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients",
abstract = "Background: Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammation in chronic obstructive pulmonary disease (COPD) patients. But, a meaningful threshold and the longitudinal changes are unknown. We aimed to investigate the association between NLR and the clinical characteristics of COPD patients and to determine a meaningful threshold and the longitudinal changes for NLR. Methods: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. We performed a blood examination and a pulmonary function test. Blood examination was completed at baseline and annually thereafter, at a time when the disease was stable. Two hundred seventy-four patients who had at least 3 blood examinations over 3 years were included. Results: Baseline NLR was correlated with baseline C-reactive protein (CRP) (r = 0.18, p = 0.003) and SAA (r = 0.34, p < 0.001). We defined an NLR score of 2.7 as the arbitrary cut-off value based on upper quartile points. COPD patients with NLR ≥ 2.7 were older (p = 0.037), had a lower BMI (p = 0.005) and a lower {\%}FEV1 (p = 0.0003) compared to patients with NLR < 2.7. Receiver-operating-characteristic (ROC) curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points. Follow-up analysis over 3 years revealed that the differences in the trends of NLR among the three groups based on the categories of exacerbations (moderate or severe, mild, no exacerbation) were significant (p = 0.006). Conclusions: NLR is associated with COPD severity and exacerbations. For predicting exacerbations, we estimated the threshold of NLR to be 2.7 at baseline.",
keywords = "Acute exacerbation, Comorbidity, COPD, NLR",
author = "Kaori Sakurai and Shotaro Chubachi and Hidehiro Irie and Akihiro Tsutsumi and Naofumi Kameyama and Takashi Kamatani and Hidefumi Koh and Takeshi Terashima and Hidetoshi Nakamura and Koichiro Asano and Tomoko Betsuyaku",
year = "2018",
month = "5",
day = "2",
doi = "10.1186/s12890-018-0639-z",
language = "English",
volume = "18",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

AU - Sakurai, Kaori

AU - Chubachi, Shotaro

AU - Irie, Hidehiro

AU - Tsutsumi, Akihiro

AU - Kameyama, Naofumi

AU - Kamatani, Takashi

AU - Koh, Hidefumi

AU - Terashima, Takeshi

AU - Nakamura, Hidetoshi

AU - Asano, Koichiro

AU - Betsuyaku, Tomoko

PY - 2018/5/2

Y1 - 2018/5/2

N2 - Background: Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammation in chronic obstructive pulmonary disease (COPD) patients. But, a meaningful threshold and the longitudinal changes are unknown. We aimed to investigate the association between NLR and the clinical characteristics of COPD patients and to determine a meaningful threshold and the longitudinal changes for NLR. Methods: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. We performed a blood examination and a pulmonary function test. Blood examination was completed at baseline and annually thereafter, at a time when the disease was stable. Two hundred seventy-four patients who had at least 3 blood examinations over 3 years were included. Results: Baseline NLR was correlated with baseline C-reactive protein (CRP) (r = 0.18, p = 0.003) and SAA (r = 0.34, p < 0.001). We defined an NLR score of 2.7 as the arbitrary cut-off value based on upper quartile points. COPD patients with NLR ≥ 2.7 were older (p = 0.037), had a lower BMI (p = 0.005) and a lower %FEV1 (p = 0.0003) compared to patients with NLR < 2.7. Receiver-operating-characteristic (ROC) curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points. Follow-up analysis over 3 years revealed that the differences in the trends of NLR among the three groups based on the categories of exacerbations (moderate or severe, mild, no exacerbation) were significant (p = 0.006). Conclusions: NLR is associated with COPD severity and exacerbations. For predicting exacerbations, we estimated the threshold of NLR to be 2.7 at baseline.

AB - Background: Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammation in chronic obstructive pulmonary disease (COPD) patients. But, a meaningful threshold and the longitudinal changes are unknown. We aimed to investigate the association between NLR and the clinical characteristics of COPD patients and to determine a meaningful threshold and the longitudinal changes for NLR. Methods: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. We performed a blood examination and a pulmonary function test. Blood examination was completed at baseline and annually thereafter, at a time when the disease was stable. Two hundred seventy-four patients who had at least 3 blood examinations over 3 years were included. Results: Baseline NLR was correlated with baseline C-reactive protein (CRP) (r = 0.18, p = 0.003) and SAA (r = 0.34, p < 0.001). We defined an NLR score of 2.7 as the arbitrary cut-off value based on upper quartile points. COPD patients with NLR ≥ 2.7 were older (p = 0.037), had a lower BMI (p = 0.005) and a lower %FEV1 (p = 0.0003) compared to patients with NLR < 2.7. Receiver-operating-characteristic (ROC) curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points. Follow-up analysis over 3 years revealed that the differences in the trends of NLR among the three groups based on the categories of exacerbations (moderate or severe, mild, no exacerbation) were significant (p = 0.006). Conclusions: NLR is associated with COPD severity and exacerbations. For predicting exacerbations, we estimated the threshold of NLR to be 2.7 at baseline.

KW - Acute exacerbation

KW - Comorbidity

KW - COPD

KW - NLR

UR - http://www.scopus.com/inward/record.url?scp=85046286423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046286423&partnerID=8YFLogxK

U2 - 10.1186/s12890-018-0639-z

DO - 10.1186/s12890-018-0639-z

M3 - Article

C2 - 29720140

AN - SCOPUS:85046286423

VL - 18

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

IS - 1

M1 - 65

ER -